







UK Health
Security
Agency

UK Standards for Microbiology Investigations

Identification of *Haemophilus* species and the HACEK group of organisms



Acknowledgments

UK Standards for Microbiology Investigations (UK SMIs) are developed under the auspices of UKHSA working in partnership with the partner organisations whose logos are displayed below and listed on [the UK SMI website](#). UK SMIs are developed, reviewed and revised by various working groups which are overseen by a [steering committee](#).

The contributions of many individuals in clinical, specialist and reference laboratories who have provided information and comments during the development of this document are acknowledged. We are grateful to the medical editors for editing the medical content.

UK SMIs are produced in association with:

Applied
Microbiology
International

Association for
Laboratory
Medicine

BIAMA
British Infection Association

BRITISH SOCIETY FOR
ANTIMICROBIAL
CHEMOTHERAPY

BRITISH SOCIETY FOR
MEDICAL MYCOLOGY
BSM

BSMT
BRITISH SOCIETY FOR
MICROBIAL TECHNOLOGY

BRITISH SOCIETY FOR PARASITOLOGY
BSP

GWYBODAETHAS • FEICROBIOLEG • CYMRU
WMA

Healthcare
Infection
Society

HSC Public Health
Agency

IBMS
Institute of
Biomedical Science

MICROBIOLOGY
SOCIETY

NHS
National
Services
Scotland

Northern Ireland Microbiology Forum and Audit Group

Public Health
Scotland

GIG
CYMRU
NHS
WALES
Iechyd Cyhoeddus
Cymru
Public Health
Wales

RCGP
Royal College of
General Practitioners

The Royal College of Pathologists
Pathology: the science behind the cure

SAM
Society for Anaerobic Microbiology

Scottish Microbiology
and Virology Network

UK Clinical Mycology Network
UK CMN
Promoting quality in Medical Mycology

THE UK CLINICAL
VIROLOGY NETWORK

UKAS
United Kingdom
Accreditation
Service

Displayed logos correct as of June 2024

Contents

Acknowledgments	2
Contents	3
Amendment table	4
1 General information	6
2 Scientific information	6
3 Scope of document	6
4 Introduction	7
5 Technical information and limitations	9
6 Safety considerations	9
7 Target organisms	10
8 Identification	10
9 Storage	16
10 Reporting	17
11 Referral to reference or specialist laboratories	18
12 Public Health responsibilities of diagnostic laboratories	18
Algorithm 1: Identification of HACEK Species	20
Algorithm 2: Identification of Haemophilus species	21
Algorithm 3: Identification of other HACEK organisms	22
References	23

Amendment table

Each UK SMI document has an individual record of amendments. The amendments are listed on this page. The amendment history is available from standards@ukhsa.gov.uk.

Any alterations to this document should be controlled in accordance with the local document control process.

Amendment number/date	9/17.07.25
Issue number discarded	5
Insert issue number	5.1
Section(s) involved	Amendment
Whole document.	<p>This is an administrative point change.</p> <p>The content of this UK SMI document has not changed.</p> <p>The last scientific and clinical review was conducted on 17/09/24.</p> <p>Hyperlinks throughout document updated to Royal College of Pathologists website.</p> <p>Public Health England replaced with UK Health Security Agency throughout the document, including the updated Royal Coat of Arms</p> <p>Partner organisation logos updated.</p> <p>Broken links to devolved administrations replaced.</p> <p>References to NICE accreditation removed.</p> <p>Scope and Purpose replaced with General and Scientific information to align with current UK SMI template.</p> <p>Public Health responsibilities of diagnostic laboratories section added.</p>

Amendment number/date	8/17.09.24
Issue number discarded	4
Insert issue number	5
Anticipated next review date*	17.09.27

Section(s) involved	Amendment
Whole document	<p>The document has been transferred into a new template and headings have been reorganised.</p> <p>The hyperlinks in the document have been updated to direct the reader to UK SMI webpages hosted on the Royal College of Pathologists website.</p> <p>The information and references in the document have been updated.</p>
Scope of document	<p>The scope has been updated to reflect the focus of the document.</p> <p>Additional links have been added to UK SMI TP 40 and other identification documents for further information.</p>
Introduction	<p>Descriptions of each species have been removed. Colonial morphology and microscopic appearance of relevant species have been summarised in table 1, section 8.2.</p>
Technical information	<p>Information has been moved to the relevant subheadings in section 8.</p>
Safety considerations	<p>References have been updated where available.</p>
Identification	<p>Subheadings have been restructured to reflect laboratory practices.</p> <p>Table 1 summarises microscopic and colonial appearance of relevant species.</p> <p>Table of biochemical test results has been removed.</p>
Reporting	<p>Information and subheadings have been updated.</p>
Referral to reference laboratory	<p>Hyperlinks have been updated.</p>
Algorithm	<p>Overarching algorithm has been added to reflect current laboratory practices.</p>
References	<p>References updated where necessary.</p>

*Reviews can be extended up to 5 years where appropriate

1 General information

[View general information](#) related to UK SMIs.

2 Scientific information

[View scientific information](#) related to UK SMIs.

3 Scope of document

This UK Standards for Microbiology Investigations (UK SMI) document describes the identification of *Haemophilus* species and other members of the HACEK group of organisms (*Aggregatibacter*, *Cardiobacterium*, *Eikenella* and *Kingella* species). It includes culture, Gram stain and matrix assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). This document mentions molecular methods for alternative identification and confirmation. Some biochemical tests may not be performed routinely in the laboratory except in cases where confirmation by an alternative technique is required or automated methods are not available.

The test procedure for MALDI-TOF MS is covered in [UK SMI TP 40: Matrix-assisted laser desorption/ionisation - time of flight mass spectrometry \(MALDI-TOF MS\) test procedure](#).

This document mentions the differentiation of *Kingella* species from pathogenic *Neisseria* and *Moraxella* species. The identification of these genera are covered in [UK SMI ID 6: Identification of *Neisseria* species](#) and [UK SMI ID 11: Identification of *Moraxella* species and morphologically similar organisms](#).

The direct identification of microorganisms from samples is beyond the scope of this document. For information related to direct identification, please refer to the other [UK SMI categories](#).

Antimicrobial Susceptibility Testing (AST) is also beyond the scope of this document. However, for effective antibiotic stewardship, laboratories should perform AST on all clinically significant isolates, particularly in cases of poor treatment response. For further information related to AST, please refer to the other UK SMI categories.

This document addresses laboratory processes for microorganism identification and is not intended for primary healthcare guidance. For relevant information please refer to the [UK SMI Syndromic documents](#).

UK SMIs should be used in conjunction with other relevant UK SMIs.

4 Introduction

4.1 Taxonomy and characteristics

Haemophilus species

The genus *Haemophilus* is part of the family Pasteurellaceae in the order Pasteurellales (1). There are currently 9 species of the genus *Haemophilus* associated with human infection (1,2). *Haemophilus aphrophilus* and *Haemophilus paraphrophilus* have been reclassified as a single species based on multilocus sequence analysis, *Aggregatibacter aphrophilus*, which includes V-factor dependent and V-factor independent isolates. *Haemophilus segnis* has been reclassified as *Aggregatibacter segnis* (3,4). *Haemophilus influenzae* is the type species.

There are six antigenically distinct capsular types of *H. influenzae*, designated 'a' to 'f' based on the polysaccharide composition of the capsular structure. Isolates that do not express a polysaccharide capsule are referred to as non-capsulated or non-typeable (5). Before the introduction of a vaccine against serotype b (Hib), the majority of infections were caused by serotype b strains, but incidence has significantly decreased following vaccination programme implementation (6). However, all types of *H. influenzae* (including non-typeable strains) can cause infections such as meningitis, bacteraemia, sepsis, otitis media and rhinosinusitis (7,8).

Other *Haemophilus* species associated with human infection are *Haemophilus aegyptius*, *Haemophilus haemolyticus*, *Haemophilus parainfluenzae*, *Haemophilus pittmaniae*, *Haemophilus parahaemolyticus*, *Haemophilus paraphrohaemolyticus*, *Haemophilus sputorum* and *Haemophilus ducreyi* (2).

Haemophilus species are fastidious, Gram negative coccobacilli or rods with marked pleomorphism. They are facultatively anaerobic, non-acid-fast, non-spore forming and non-motile (9). All species require either or both of two growth factors for growth: haemin (factor X) and/or nicotinamide adenine dinucleotide (factor V), which can be used to aid identification of species (2).

Other HACEK group of organisms

A systematic approach is used to differentiate the HACEK group of clinically encountered, morphologically similar, aerobic, and facultatively anaerobic Gram negative rods mainly associated with endocarditis and infections from normally sterile sites. These organisms are oropharyngeal/respiratory tract commensals (10,11).

Aggregatibacter species

Aggregatibacter species are members of the family Pasteurellaceae. The genus *Aggregatibacter* contains 4 species, *Aggregatibacter actinomycetemcomitans*, *Aggregatibacter aphrophilus*, *Aggregatibacter segnis* and *Aggregatibacter kilianii*. The type species is *Aggregatibacter actinomycetemcomitans* (1).

A. actinomycetemcomitans has been found in periodontitis, endocarditis, brain abscess and urinary tract infections (3,12).

Aggregatibacter species are Gram negative, non-motile, facultatively anaerobic, pleomorphic rods or coccobacilli (13). There is no dependence on X factor and the requirement for V factor is variable.

The species of the genus are intimately associated with humans. They are often recovered as part of the human oral flora, but are occasionally recovered from other body sites, including blood and brain, or as causes of infective endocarditis and abscesses (10).

Cardiobacterium species

The genus *Cardiobacterium* are members of the Cardiobacteriaceae family. The genus *Cardiobacterium* contains 2 species, *Cardiobacterium hominis* and *Cardiobacterium valvarum*. *C. hominis* is the type species (1,14). They are Gram negative, facultatively anaerobic, pleomorphic or straight rods and are arranged singly, in pairs, in short chains and in rosette clusters (15).

Eikenella species

The genus *Eikenella* is part of the Neisseriaceae family. Currently there are 5 species within the genus *Eikenella*. The type species is *Eikenella corrodens*, which is a coloniser of the oral mucous membranes, the upper respiratory tract and possibly the gastrointestinal tract. Other species include *Eikenella exigua*, *Eikenella glucosivorans*, *Eikenella halliae*, *Eikenella loninqua* (1). *Eikenella* species are Gram negative, facultatively anaerobic (except for *E. loninqua*) small rods with occasional filaments. They are non-motile; however, some species exhibit a “twitching” motility (16,17).

Kingella species

The genus *Kingella* is in the Neisseriaceae family and comprises of five species, *Kingella kingae*, *Kingella denitrificans*, *Kingella potus* and *Kingella oralis*, *Kingella negevensis*, with *K. kingae* being the type species (1). *Kingella indologenes* has been transferred to a new genus and classified as *Suttonella indologenes* (18). They are Gram negative, non-motile straight rods. They occur in pairs and sometimes short chains (19).

Kingella species may grow on Neisseria selective agar and therefore may be misidentified as pathogenic *Neisseria* species. The strain can be differentiated from *Moraxella* and *Neisseria* species by a catalase test. Most *Kingella* species are catalase negative; *Moraxella* and most *Neisseria* species (except *Neisseria elongata*) are catalase positive.

5 Technical information and limitations

With improvements to molecular taxonomy, some species previously included in the *Haemophilus* genus have been reclassified into the *Aggregatibacter* genus (3). Whilst no longer in the same genus, identification of these species can be difficult due to similarities in characteristics.

Clinicians are encouraged to stay informed about any further taxonomy changes and consider these when interpreting laboratory results. Changes in taxonomy should be considered when using commercial identification systems. Laboratories should ensure all databases, including MALDI-TOF MS, are regularly updated to reduce potential misidentification.

6 Safety considerations

The section covers specific safety considerations (20-40) related to this UK SMI, and should be read in conjunction with the general [safety considerations](#).

All HACEK species are Hazard Group 2 organisms and processing of diagnostic samples should be carried out at Containment Level 2.

H. influenzae is a Hazard Group 2 organism, and in some cases the nature of the work may dictate full Containment Level 3 conditions. All laboratories should handle specimens as if potentially high risk.

H. influenzae can cause serious invasive disease, especially in young children. Laboratory-acquired infections have been reported. The organism infects primarily by the respiratory route, autoinoculation or ingestion in laboratory workers (41).

Laboratory procedures that give rise to infectious aerosols must be conducted in a microbiological safety cabinet.

For safety considerations for individual tests, please see [UK SMI Test Procedures documents](#)

The above guidance should be supplemented with local COSHH and risk assessments.

Compliance with postal and transport regulations is essential.

7 Target organisms

Please refer to Table 1 for all HACEK species associated with human disease.

8 Identification

Identification of *Haemophilus* and other HACEK species requires a combination of methods. Colonies on blood or chocolate agar may be presumptively identified by colonial morphology, microscopy, requirement for X and V factors and MALDI-TOF MS. Biochemical tests can be used in laboratories when MALDI-TOF MS is unavailable. If confirmation or further identification is required, samples are transported to reference or specialised testing laboratories.

8.1 Culture methods

Culture can be used to provide presumptive identification of HACEK organisms. Initial assessments of colonial morphology can dictate future testing when investigating potential HACEK isolates. Following presumptive identification, further techniques, including MALDI-TOF MS or biochemical tests can be used to further identify the species.

8.1.1 Bacterial growth medium

Haemophilus species require enriched media to support growth. They require X and/or V factor. This can be added to medium unless chocolate blood agar is used (42). For the growth of *H. ducreyi* and *H. aegyptius*, growth medium should be further supplemented with growth factors, which are commercially available as a supplement (42).

All HACEK species are facultative anaerobes and grow best with 5-10% CO₂ present. HACEK species are slow growing and therefore most colonies can take between 24 and 48 hours, however *E. exiguus* and *C. valarum* can take up to 72 hours to become visible (17,43).

Primary isolation media

For *Haemophilus* species, incubation for 24-48 hours with enriched 5% chocolatised sheep blood agar at 35-37°C with 5-10% CO₂ is preferred (44). Blood agar can be used instead of chocolate agar, providing free V and X factor are supplemented.

Other HACEK species can be incubated for 24-48 hours on either chocolate blood agar or blood agar at 35-37°C with 5-10% CO₂ present (45).

Selective media

Haemophilus selective agar is commercially available and contains horse blood and antibiotics (kanamycin and vancomycin). If not already present, bacitracin can be added to media, or bacitracin discs applied to the surface of inoculated agar to inhibit *Neisseria* species. Cultures should be incubated at 35-37°C with 5-10% CO₂ for 24-48 hours (42).

Selective media for *A. actinomycetemcomitans* is commercially available. Samples should be incubated at 35-37°C for 18-24 hours under anaerobic conditions (45).

8.1.2 Colonial appearance

Colonial appearance varies significantly with species, however generally:

- *Haemophilus* species produce colonies that are flat, convex and grey-white on blood agar (9).
- *Aggregatibacter* species produce colonies that are greyish-white/yellow, granular and rough (13)
- *Cardiobacterium* species produce smooth, convex and opaque colonies (15)
- *Eikenella* species produce colonies that may corrode the agar (16)
- *Kingella* species produce either spreading/corroding colonies or smooth, convex colonies (19)

For detailed descriptions of each species refer to section 8.2, Table 1. Refer to section 8.4.1, Table 2 for a summary of haemolysis of *Haemophilus* species on blood agar.

8.2 Microscopic appearance

8.2.1 Gram stain

Please refer to [UK SMI TP 39 - Staining procedures](#).

All HACEK species are Gram negative; however, some species may stain weakly.

- *Haemophilus* species are small-medium sized pleomorphic rods; however, spheres and coccobacilli can be seen (9)
- *Aggregatibacter* species tend to be rod-shaped, but coccobacilli can also be observed (13)
- *Cardiobacterium* species are straight rods with rounded ends and occasional long filaments (15)

Identification of *Haemophilus* species and the HACEK group of organisms

- *Eikenella* species are usually straight, unbranched rods with rounded edges (16)
- *Kingella* species are straight rods with rounded/square ends. *K. kingae* does not Gram stain well (19)

For information on the microscopic appearance of individual species refer to table 1 below.

Table 1: Microscopic and Colonial appearance of HACEK species (9,13,17,42,43,46-52)

Please note that the information in this table provides general characteristics of colony appearance and can vary among different strains and culture conditions.

Species	Appearance	Additional Comments
<i>H. influenzae</i>	Small, regular rods that can be mixed with coccobacilli. Colonies are smooth, low, convex, greyish, translucent. Encapsulated strains can appear mucoid. Non-encapsulated strains produce small, buff colonies.	Indole producing strains have an amine-like odour.
<i>H. aegyptius</i>	Slow-growing colonies. Colonies produced are smooth, low, convex and translucent.	Grow to 0.5mm diameter in 48 hours
<i>H. ducreyi</i>	Slender rods. Colonies are small, flat, smooth and grey. Larger colonies are sometimes seen mixed with smaller colonies.	Grows poorly. Can take 3-5 days to become visible. Can be surrounded by small zone of β -haemolysis.
<i>H. pittmaniae</i>	Small pleomorphic rods with occasional filamentous forms. Colonies are convex and grey-white.	None
<i>H. parainfluenzae</i>	Small pleomorphic rods interspersed with filamentous forms. Colonies are off-white to yellow coloured. Colony appearance can vary. They can be flat and smooth or granular or wrinkled.	Some strains show β haemolysis. Colony appearance may change with age.
<i>H. haemolyticus</i>	Small, regular rods or spheres with occasional filamentous forms. Colonies are translucent, smooth, and convex.	Produce a clear zone of β -haemolysis.
<i>H. parahaemolyticus</i>	Small, regular rods with occasional filamentous forms. Smooth colonies similar to <i>H. parainfluenzae</i> .	Produce zone β -haemolysis.
<i>H. paraphrohaemolyticus</i>	Small rods. Colonies similar to <i>H. haemolyticus</i> .	None
<i>H. sputorum</i>	Small regular rods, occasionally spheres. Colonies are convex, whiteish and opaque	Produce β -haemolysis on horse/sheep agar but some strains are non-haemolytic.

Identification of *Haemophilus* species and the HACEK group of organisms

Species	Appearance	Additional Comments
<i>A. actinomycetemcomitans</i>	Small pleomorphic rods. Rough, tenacious colonies with an internal, opaque pattern.	Colonies can be sticky if slime is produced.
<i>A. aphrophilus</i>	Short regular rods with occasional filamentous forms. Colonies are convex, opaque, granular, and yellowish.	None
<i>A. segnis</i>	Small pleomorphic rods, sometimes with irregular filamentous forms. Colonies are slow growing. They are smooth, granular, convex, greyish-white, and opaque.	None
<i>A. kilianii</i>	Short regular rods with occasional filamentous forms. Supplemented with CO ₂ colonies are granular, yellowish, and opaque. Without CO ₂ colonies are small with larger colonies interspersed.	None
<i>C. hominis</i>	Small colonies produced unless in a humid atmosphere. Colonies are circular, smooth, moist and opaque.	Colonies can cause some α -haemolysis.
<i>E. corrodens</i>	Colonies are small with a moist clear centre surrounded by flat spreading growth. Pitting of the medium can occur.	Non-haemolytic. Older cultures can turn yellow.
<i>K. denitrificans</i>	Colonies are small and translucent. They may show pitting of the medium.	None
<i>K. kingae</i>	Colonies produce small depressions. They have a central paila and spreading growth with granular zones surrounding. Colonies can also be small, delicate, translucent/opaque.	Colonies can cause β -haemolysis.
<i>K. oralis</i>	Colonies are round with irregular borders. They are flat to umbonate with a granular periphery.	None
<i>K. potus</i>	Colonies are circular, convex, and smooth. They are often yellow pigmented.	Non-haemolytic.
<i>K. negevensis</i>	Colonies are round and smooth. They can be pale yellow in colour.	Colonies are β -haemolytic.

8.3 Matrix-Assisted Laser Desorption/Ionisation - Time of Flight Mass Spectrometry (MALDI-TOF MS)

MALDI-TOF MS is used as the primary method for the identification of HACEK species in diagnostic laboratories. Therefore, it is important that this method is appropriately validated, manufacturer instructions carefully followed, available

database updates are installed and reviewed, and the use of an extraction step that can contribute to a more reliable species identification is considered.

MALDI-TOF MS is used for the identification of several *Haemophilus* species, including *H. influenzae*, *H. parainfluenzae*, and *H. parahaemolyticus* (53,54). Databases that are used only for research may include other *Haemophilus* species including *H. haemolyticus*, however it should be noted that MALDI-TOF MS can incorrectly identify *H. haemolyticus* isolates as *H. influenzae* or *H. parainfluenzae* (55). In the case of suspected misidentification, results should be interpreted carefully, and further biochemical tests or molecular methods are recommended.

This technique accurately identifies members of the other HACEK genera, despite their fastidious nature (54,56). MALDI-TOF MS is effective for identification of *Aggregatibacter* species, *C. hominis*, *E. corrodens* and *K. kingae* (57). Some species, including *A. killianii*, *K. negevensis* and any new species resulting from taxonomy changes may not be included in the analyser databases. Laboratories are encouraged to check the MALDI-TOF MS databases used if these organisms are suspected. Biochemical testing is recommended for species not represented in the MALDI-TOF MS databases.

8.4 Further identification

8.4.1 Biochemical tests and commercial identification systems

Biochemical tests are no longer routine in laboratories but are used in cases when MALDI-TOF MS is unavailable or when MALDI-TOF MS results are inconclusive. Discrepancies in test results should be referred to the appropriate reference or specialist laboratories for further testing. Refer to manufacturer's guidance or other relevant sources for biochemical properties of individual HACEK species (42,45). Algorithms 2 and 3 contain examples of biochemical tests that may be used to differentiate between HACEK organisms.

Several commercial identification systems that use biochemical or enzymatic substrates are available for identification of *Haemophilus* species. The manufacturer's instructions should be followed precisely when using these kits. In many cases, the commercial identification system may not reflect recent changes in taxonomy.

X and V factor test

Please refer to [UK SMI TP 38 – X and V Factor Test](#)

Haemophilus species have a requirement for V factor, which can be helpful in species identification. X and V factor test can provide initial information on the species. Porphyrin tests can identify X factor dependent species. Negative porphyrin tests

suggest X factor dependence. Please refer [to UK SMI TP 29 – Porphyrin synthesis \(ALA\) test](#).

For X & V factor requirements of the relevant *Haemophilus* species see table 2 below.

The X and V factor testing should be performed using a minimal nutrient agar, such as basic nutrient agar, but for which the X and V discs have been validated as any trace X or V factors could influence the results. Manufacturers' instructions should be followed when performing this test.

Table 2: Summary of Haemolysis and X/V factor requirements (42)

Organism	X factor	V factor	Haemolysis
<i>H. influenzae</i> ^a	+	+	-
<i>H. parainfluenzae</i>	-	+	-
<i>H. haemolyticus</i> ^b	+	+	+
<i>H. parahaemolyticus</i>	-	+	+
<i>H. paraphrohaemolyticus</i>	-	+	+
<i>H. aegyptius</i>	+	+	-
<i>H. pittmaniae</i>	-	+	+
<i>H. sputorum</i>	-	+	+
<i>H. ducreyi</i>	+	-	-
^a <i>H. aegyptius</i> is indistinguishable from <i>H. influenzae</i> biotype III in normal laboratory tests. ^b Traditionally described as β-haemolytic on horse blood agar, but non-haemolytic strains exist (2) +; factor is required for growth -; factor is not required for growth			

8.4.2 Serotyping *H. influenzae* with commercial type-specific antisera and PCR

If *H. influenzae* is detected, serotyping should be performed using slide agglutination or PCR testing. The presence of capsule polysaccharide can be detected by slide agglutination using commercial antisera. If positive, the individual serotype (a to f) can also be determined using antisera. Slide agglutination can sometimes generate ambiguous results and so the capsule type can be confirmed using multiple PCRs targeting regions within the capsule gene operon (58,59).

Some multi-species meningitis latex agglutination detection kits include antiserum against *H. influenzae* serotype b alone because of its historical dominance in causing meningitis and its relevance in detecting vaccine failures. However, it should be noted

that not all latex agglutination detection kits are suitable for use on bacterial suspensions of *H. influenzae* (according to the manufacturer's instructions).

8.4.3 Molecular Methods

Molecular techniques have made identification of many species more rapid and precise than is possible with phenotypic techniques. However, some of these methods are difficult to implement for routine bacterial identification in a clinical laboratory and may be better sourced from a reference laboratory.

Other tests such as nucleic acid amplification tests have been developed to identify *H. influenzae* and *H. parainfluenzae* in clinical specimens and some have been incorporated into commercial multi-pathogen detection systems (60). A commercial multiplex PCR assay has been developed that permits the simultaneous amplification of DNA targets from *H. ducreyi*, *Treponema pallidum*, and Herpes Simplex Virus types 1 and 2 directly from genital ulcer specimens (61).

A genotypic identification method, 16S rRNA gene sequencing has been used for better discrimination of closely related species such as *C. hominis* and *C. valvarum* (43,62). It has equally been used for identifying *Haemophilus* and *Aggregatibacter* species (2).

Next Generation Sequencing

Metagenomic NGS has been used to confirm identification of *A. segnis* and *H. influenzae* (63,64). Whilst currently limited to reference laboratories, NGS could become more accessible to diagnostic laboratories, however its performance compared to current gold standard methods still needs to be established.

9 Storage

For short term storage of *H. influenzae* and other HACEK organisms, isolates should be preserved on a chocolate agar slope at room temperature (45,65).

For long term storage of HACEK species, isolates should be frozen at -20°C to -80°C in a cryoprotective solution such as glycerol (45,66).

If required, save pure isolates on a chocolate agar slope for referral to the reference laboratory.

10 Reporting

10.1 Infection Specialist

Inform the medical microbiologist of all positive cultures from normally sterile sites.

Invasive *H. Influenzae* should be reported for surveillance purposes.

Certain clinical conditions must be notified to the laboratory associated infection specialist. Typically, these will include:

- Facial cellulitis
- Septic arthritis
- Osteomyelitis
- Epiglottitis, pneumonia, mastoiditis or empyema thoracis

Follow local protocols for reporting to clinician.

10.2 Presumptive identification

If appropriate growth characteristics, colonial appearance and Gram stain of the culture are demonstrated.

10.3 Confirmation of identification

Following identification, serotyping of *H. influenzae* can be obtained from the reference or specialist laboratory.

For confirmation and identification please see [Specialist and reference microbiology: laboratory tests and services page on GOV.UK](#) for reference laboratory user manuals and request forms.

10.4 Health Protection Team (HPT)

Refer to local agreements in devolved administrations.

10.5 UK Health Security Agency

Refer to current guidelines on Second Generation Surveillance System (SGSS) reporting (67).

10.6 Infection prevention and control team

N/A

11 Referral to reference or specialist laboratories

If isolates are being transported to laboratories for further testing, ensure specimen is placed in a sealed container within appropriate packaging, following all relevant transport regulations. If required, save pure isolate on a chocolate agar slope for referral to the reference laboratory.

Isolates of invasive *H. influenzae* from normally sterile sites should be sent to the Vaccine Preventable Bacteria Section, Respiratory and Vaccine Preventable Bacteria Reference Unit (RVPBRU), UK Health Security Agency (UKHSA) for confirmation and typing.

For information on the tests offered, turnaround times, transport procedure and the other requirements of the reference or specialist laboratory [see user manuals and request forms](#)

Organisms with unusual/unexpected resistance, associated with a laboratory/clinical problem or an anomaly that requires investigation should be sent to the appropriate reference laboratory.

Contact appropriate reference or specialist laboratory for information on the tests available, turnaround times, transport procedure and any other requirements for sample submission:

[England](#)

[Wales](#)

[Scotland](#)

[Northern Ireland](#)

12 Public Health responsibilities of diagnostic laboratories

Diagnostic laboratories have public health responsibility as part of their duties. Amongst these are additional local testing, or referral, to further characterise the organism, as required, primarily for public health purposes e.g. routine cryptosporidium detection; serotyping or microbial subtyping; and a duty to refer appropriate specimens and isolates of public health importance to a reference laboratory.


Diagnostic laboratory outputs inform public health intervention, and surveillance data is required to develop policy and guidance, forming an essential component of

Identification of *Haemophilus* species and the HACEK group of organisms

healthcare. It is recognised that additional testing and referral of samples may entail some costs that has to be borne by the laboratory but in certain jurisdictions these costs are covered centrally.

Diagnostic laboratories should be mindful of the impact of laboratory investigations on public health and consider requests from the reference laboratories for specimen referral or enhanced information.


Algorithm 1: Identification of HACEK Species



This flowchart is for guidance only.

Algorithm 2: Identification of *Haemophilus* species


This flowchart provides a summary some common biochemical tests to supplement algorithm 1. This flowchart is for guidance only.



* 11- 89% strains positive
** weakly positive

Algorithm 3: Identification of other HACEK organisms

This flowchart provides a summary of some common biochemical tests to supplement algorithm 1. This flowchart is for guidance only.



*variable results

References

An explanation of the reference assessment used is available in the [scientific information section](#).

1. Parte AC and others. List of Prokaryotic names with Standing in Nomenclature (LPSN) moves to the DSMZ. *Int J Syst Evol Microbiol* 2020: volume 70, issue 11, pages 5607-12.++ <https://doi.org/10.1099/ijsem.0.004332>
2. Nørskov-Lauritsen N. Classification, Identification, and Clinical Significance of *Haemophilus* and *Aggregatibacter* Species with Host Specificity for Humans. *Clinical Microbiology Reviews* 2014: volume 27, issue 2, pages 214-40.+ <https://doi.org/10.1128/cmr.00103-13>
3. Nørskov-Lauritsen N, Kilian M. Reclassification of *Actinobacillus actinomycetemcomitans*, *Haemophilus aphrophilus*, *Haemophilus paraphrophilus* and *Haemophilus segnis* as *Aggregatibacter actinomycetemcomitans* gen. nov., comb. nov., *Aggregatibacter aphrophilus* comb. nov. and *Aggregatibacter segnis* comb. nov., and emended description of *Aggregatibacter aphrophilus* to include V factor-dependent and V factor-independent isolates. *International Journal of Systematic and Evolutionary Microbiology* 2006: volume 56, issue Pt 9, pages 2135-46.2+ <https://doi.org/10.1099/ijms.0.64207-0>
4. Chien Y-C and others. Clinical characteristics of bacteremia caused by *Haemophilus* and *Aggregatibacter* species and antimicrobial susceptibilities of the isolates. *Journal of Microbiology, Immunology and Infection* 2021: volume 54, issue 6, pages 1130-8.3+ <https://doi.org/10.1016/j.jmii.2020.12.002>
5. Wen S and others. Molecular epidemiology and evolution of *Haemophilus influenzae*. *Infection, Genetics and Evolution* 2020: volume 80.+ <https://doi.org/10.1016/j.meegid.2020.104205>
6. Park JJ and others. Estimating the global and regional burden of meningitis in children caused by *Haemophilus influenzae* type b: A systematic review and meta-analysis. *Journal of Global Health* 2022: volume 12.1++ 10.7189/jogh.12.04014
7. Ulanova M, Tsang RSW. *Haemophilus influenzae* serotype a as a cause of serious invasive infections. *The Lancet Infectious Diseases* 2014: volume 14, issue 1, pages 70-82.+ [https://doi.org/10.1016/S1473-3099\(13\)70170-1](https://doi.org/10.1016/S1473-3099(13)70170-1)
8. Bertran M and others. Trends in invasive *Haemophilus influenzae* serotype a disease in England from 2008–09 to 2021–22: a prospective national surveillance study. *The Lancet Infectious Diseases* 2023: volume 23, issue 10, pages 1197-206.2+ [https://doi.org/10.1016/S1473-3099\(23\)00188-3](https://doi.org/10.1016/S1473-3099(23)00188-3)

9. Bergey's Manual of Systematics of Archaea and Bacteria *Haemophilus*; 2021. pages 1-22. ++ <https://doi.org/10.1002/9781118960608.gbm01198.pub2>
10. Khaledi M and others. Infective endocarditis by HACEK: a review. *Journal of Cardiothoracic Surgery* 2022: volume 17, issue 1, pages 185.++ 10.1186/s13019-022-01932-5
11. Chambers ST and others. HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort. *PLOS ONE* 2013: volume 8, issue 5.2+ 10.1371/journal.pone.0063181
12. Oscarsson J and others. Tools of *Aggregatibacter actinomycetemcomitans* to Evade the Host Response. *Journal of Clinical Medicine* 2019: volume 8, issue 7, pages 1079.+
13. Bergey's Manual of Systematics of Archaea and Bacteria *Aggregatibacter*; 2021. pages 1-9. ++ <https://doi.org/10.1002/9781118960608.gbm01839>
14. Han XY and others. Endocarditis with ruptured cerebral aneurysm caused by *Cardiobacterium valvarum* sp. nov. *Journal of Clinical Microbiology* 2004: volume 42, issue 4, pages 1590-5.3+
15. Bergey's Manual of Systematics of Archaea and Bacteria *Cardiobacterium*; 2015. pages 1-6. ++ <https://doi.org/10.1002/9781118960608.gbm01101>
16. Bergey's Manual of Systematics of Archaea and Bacteria *Eikenella*; 2015. pages 1-11. ++ <https://doi.org/10.1002/9781118960608.gbm00976>
17. Bernard KA and others. Description of *Eikenella halliae* sp. nov. and *Eikenella longinqua* sp. nov., derived from human clinical materials, emendation of *Eikenella exigua* Stormo et al. 2019 and emendation of the genus *Eikenella* to include species which are strict anaerobes. *International Journal of Systematic and Evolutionary Microbiology* 2020: volume 70, issue 5, pages 3167-78.3+ 10.1099/ijsem.0.004150
18. Dewhirst FE and others. Transfer of *Kingella indologenes* (Snell and Lapage 1976) to the genus *Suttonella* gen. nov. as *Suttonella indologenes* comb. nov.; transfer of *Bacteroides nodosus* (Beveridge 1941) to the genus *Dichelobacter* gen. nov. as *Dichelobacter nodosus* comb. nov.; and assignment of the genera *Cardiobacterium*, *Dichelobacter*, and *Suttonella* to *Cardiobacteriaceae* fam. nov. in the gamma division of *Proteobacteria* on the basis of 16S rRNA sequence comparisons. *International Journal of Systematic Bacteriology* 1990: volume 40, issue 4, pages 426-33.3+
19. Bergey's Manual of Systematics of Archaea and Bacteria *Kingella*; 2015. pages 1-8. ++ <https://doi.org/10.1002/9781118960608.gbm00979>

20. Advisory Committee on Dangerous Pathogens. The Approved List of Biological Agents. Health and Safety Executive 2023. pages 1-39. ++
21. British Standards Institution (BSI). BS 5726:2005 - Microbiological safety cabinets. Information to be supplied by the purchaser and to the vendor and to the installer, and siting and use of cabinets. Recommendations and guidance. 2005. pages 1-14. ++
22. British Standards Institution (BSI). BS EN12469 - Biotechnology - performance criteria for microbiological safety cabinets 2000. ++
23. Centers for Disease Control and Prevention. Guidelines for Safe Work Practices in Human and Animal Medical Diagnostic Laboratories. MMWR Surveill Summ 2012: volume 61, pages 1-102.+
24. Department for Transport and others. Transport of infectious substances UN2814, UN2900 and UN3373 Guidance note number 17/2012 (revision 7). 2013. ++
25. Department of Health. Health Protection Legislation (England) Guidance. pages 1-112. 2010. ++
26. Gizzie N, Adukwu E. Evaluation of Liquid-Based Swab Transport Systems against the New Approved CLSI M40-A2 Standard. J Clin Microbiol 2016: volume 54, issue 4, pages 1152-6.2+ 10.1128/JCM.03337-15
27. Health and Safety Executive. Control of Substances Hazardous to Health Regulations. The Control of Substances Hazardous to Health Regulations 2002 (as amended). Approved Code of Practice and guidance L5 (sixth edition). HSE Books. 2013. ++
28. Health and Safety Executive, Advisory Committee on Dangerous Pathogens. Management and operation of microbiological containment laboratories. HSE. 2019. ++
29. Health and Safety Executive. Risk assessment: A brief guide to controlling risks in the workplace. HSE. 2014. ++
30. Health and Safety Executive. Safe use of pneumatic air tube transport systems for pathology specimens. 2009. ++
31. Health Services Advisory Committee. Safe Working and the Prevention of Infection in Clinical Laboratories and Similar Facilities. HSE Books 2003. ++
32. Home Office. Anti-terrorism, Crime and Security Act. 2001. ++
33. Home Office. Public Health Act (Northern Ireland) 1967 Chapter 36. 1967. ++

34. Official Journal of the European Communities. Directive 98/79/EC of the European Parliament and of the Council of 27 October 1998 on *in vitro* diagnostic medical devices 1998. pages 1-37. ++
35. UKHSA. Laboratory reporting to UKHSA: a guide for diagnostic laboratories. UKHSA 2023. pages 1-31. ++
36. Scottish Government. Public Health (Scotland) Act. 2008. ++
37. The Royal College of Pathologists. The retention and storage of pathological records and specimens (5th edition). pages 1-59. 2015. ++
38. The Welsh Assembly Government. Health Protection Legislation (Wales) Guidance. 2010. ++
39. Tyrrell KL and others. Comparison of the Copan eSwab System with an Agar Swab Transport System for Maintenance of Fastidious Anaerobic Bacterium Viability. J Clin Microbiol 2016: volume 54, issue 5, pages 1364-7. **2+**
10.1128/JCM.03246-15
40. World Health Organization. Guidance on regulations for the transport of infectious substances 2021-2022. WHO. 2021. ++
41. Jacobson JT and others. Infections acquired in clinical laboratories in Utah. Journal of Clinical Microbiology 1985: volume 21, issue 4, pages 486-9. **3-**
42. Manual of Clinical Microbiology *Haemophilus* Washington DC: ASM Press; 2023. ++
<https://www.clinmicronow.org/doi/10.1128/9781683670438.MCM.ch37>
43. Chen M and others. *Cardiobacterium valvarum* infective endocarditis and phenotypic/molecular characterization of 11 *Cardiobacterium* species strains. Journal of Medical Microbiology 2011: volume 60, issue Pt 4, pages 522-8. **3+**
<https://doi.org/10.1099/jmm.0.025353-0>
44. Harris TM and others. Culture of non-typeable *Haemophilus influenzae* from the nasopharynx: Not all media are equal. Journal of Microbiological Methods 2017: volume 137, pages 3-5. <https://doi.org/10.1016/j.mimet.2017.03.012>
45. Manual of Clinical Microbiology *Aggregatibacter*, *Capnocytophaga*, *Eikenella*, *Kingella*, *Pasteurella* and Other Fastidious or Rarely Encountered Gram-Negative Rods Washington DC: ASM Press; 2023. ++
<https://www.clinmicronow.org/doi/10.1128/9781683670438.MCM.ch36>
46. Slotnick IJ, Dougherty M. Further characterization of an unclassified group of bacteria causing endocarditis in man: *Cardiobacterium hominis* gen. et sp. n. Antonie Van Leeuwenhoek 1964: volume 30, pages 261-72. **3+**
10.1007/BF02046732

47. Dewhirst FE and others. Chromobacterium, Eikenella, Kingella, Neisseria, Simonsiella, and Vitreoscilla Species Comprise a Major Branch of the Beta Group Proteobacteria by 16S Ribosomal Ribonucleic Acid Sequence Comparison: Transfer of Eikenella and Simonsiella to the Family Neisseriaceae (emend.). International Journal of Systematic Bacteriology 1989: volume 39, issue 3, pages 258-66.**2+** <https://doi.org/10.1099/00207713-39-3-258>
48. Hollis DG and others. Emended description of Kingella denitrificans (Snell and Lapage 1976): correction of the maltose reaction. Journal of Clinical Microbiology 1983: volume 18, issue 5, pages 1174-6.**3+** 10.1128/jcm.18.5.1174-1176.1983
49. Henriksen SD, Bovre K. Transfer of *Moraxella kingae* Henriksen and Bovre to the Genus *Kingella* gen. nov. in the family *Neisseriaceae*. International Journal of Systematic Bacteriology 1976: volume 26, issue 4, pages 447-50.**+** <https://doi.org/10.1099/00207713-26-4-447>
50. Dewhirst FE and others. Phylogeny of species in the family Neisseriaceae isolated from human dental plaque and description of Kingella oralis sp. nov [corrected]. International Journal of Systematic Bacteriology 1993: volume 43, issue 3, pages 490-9.**3+** 10.1099/00207713-43-3-490
51. Lawson PA and others. Description of Kingella potus sp. nov., an organism isolated from a wound caused by an animal bite. Journal of Clinical Microbiology 2005: volume 43, issue 7, pages 3526-9.**3+** 10.1128/JCM.43.7.3526-3529.2005
52. El Houmami N and others. Isolation and characterization of Kingella negevensis sp. nov., a novel Kingella species detected in a healthy paediatric population. International Journal of Systematic and Evolutionary Microbiology 2017: volume 67, issue 7, pages 2370-6.**3+** 10.1099/ijsem.0.001957
53. Branda JA and others. Multicenter validation of the VITEK MS v2.0 MALDI-TOF mass spectrometry system for the identification of fastidious gram-negative bacteria. Diagnostic Microbiology and Infectious Disease 2014: volume 78, issue 2, pages 129-31.**2+** <https://doi.org/10.1016/j.diagmicrobio.2013.08.013>
54. Almuzara M and others. Performance of MALDI-TOF mass spectrometry for the identification of the HACEK group and other fastidious gram-negative rods. Open Microbiology Journal 2019: volume 13, issue 1, pages 216-21.**2+** 10.2174/1874285801913010125
55. Nürnberg S and others. Discriminative Potential of the Vitek MS In Vitro Diagnostic Device Regarding Haemophilus influenzae and Haemophilus haemolyticus. Journal of Clinical Microbiology 2020: volume 58, issue 9.**2+** 10.1128/jcm.00278-20

56. Powell EA and others. Application of Matrix-Assisted Laser Desorption Ionization–Time of Flight Mass Spectrometry for Identification of the Fastidious Pediatric Pathogens *Aggregatibacter*, *Eikenella*, *Haemophilus*, and *Kingella*. *Journal of Clinical Microbiology* 2020: volume 51, issue 11, pages 3862-4. **2++** 10.1128/jcm.02233-13
57. Couturier MR and others. Identification of HACEK clinical isolates by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *Journal of Clinical Microbiology* 2011: volume 49, issue 3, pages 1104-6. **2+** 10.1128/JCM.01777-10
58. Falla TJ and others. PCR for capsular typing of *Haemophilus influenzae*. *Journal of Clinical Microbiology* 1994: volume 32, issue 10, pages 2382-6. **2+** 10.1128/jcm.32.10.2382-2386.1994
59. Wroblewski D and others. Utilization of a real-time PCR approach for *Haemophilus influenzae* serotype determination as an alternative to the slide agglutination test. *Mol Cell Probes* 2013: volume 27, issue 2, pages 86-9. **3+** 10.1016/j.mcp.2012.11.003
60. Tian GZ and others. Rapid Detection of *Haemophilus influenzae* and *Haemophilus parainfluenzae* in Nasopharyngeal Swabs by Multiplex PCR. *Biomedical and Environmental Sciences* 2012: volume 25, issue 3, pages 367-71. **2+** <https://doi.org/10.3967/0895-3988.2012.03.016>
61. Orle KA and others. Simultaneous PCR detection of *Haemophilus ducreyi*, *Treponema pallidum*, and herpes simplex virus types 1 and 2 from genital ulcers. *Journal of Clinical Microbiology* 1996: volume 34, issue 1, pages 49-54. **2+** 10.1128/jcm.34.1.49-54.1996
62. Hoffman MJ and others. Prosthetic valve/conduit infection caused by *Cardiobacterium valvarum*. *Infection* 2010: volume 38, issue 3, pages 245-6. **2-** 10.1007/s15010-010-0004-5 [doi]
63. Morsli M and others. *Haemophilus influenzae* Meningitis Direct Diagnosis by Metagenomic Next-Generation Sequencing: A Case Report. 2021. **3+** 10.3390/pathogens10040461
64. Guo X and others. Endocarditis due to *Aggregatibacter Segnis*: a rare case report. *BMC Infectious Diseases* 2023: volume 23, issue 1, pages 309. **3+** 10.1186/s12879-023-08231-x
65. Khushboo Prajapati SR, Summaiya Mullan. Different Preservation Methods for Long Term Maintenance of *Haemophilus influenzae*. *Advances in Microbiology* 2017: volume 7, pages 343-8. **3+** doi.org/10.4236/aim.2017.75028.

Identification of *Haemophilus* species and the HACEK group of organisms

66. Villa L and others. Long term storage of fastidious bacteria (*Neisseria* spp. and *Haemophilus* spp.) with swab preservation at -80 °C. *Journal of Microbiological Methods* 2020: volume 175, pages 105969. **2+** 10.1016/j.mimet.2020.105969
67. UKHSA. Laboratory reporting to UKHSA: a guide for diagnostic laboratories. UKHSA 2023. pages 1-31. **++**